Release Date: December 17, 2025
Expiration Date: December 17, 2026
Activity Overview
The treatment of gastroesophageal adenocarcinoma (GEA) has undergone significant transformation as novel targeted and immunotherapies have been developed. In particular, multiple treatment approaches are now available for the management of HER2-positive disease across the treatment continuum for metastatic disease, with new therapeutic options poised to join the therapeutic arsenal.
This podcast features a discussion of management of toxicities associated with currently available and emerging treatment approaches for HER2-positive GEA, led by Rohit Gosain, MD; and Rahul Gosain, MD, and featuring 2 faculty experts focused on the management of these tumors.
Target Audience
This educational activity is directed toward US and global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA and BTC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review common and severe adverse events associated with HER2-targeting therapies and analyze trial data to understand mitigation strategies for relevant AEs
- Develop practical approaches to patient education, early AE recognition, and supportive care, emphasizing multidisciplinary collaboration to optimize outcomes and adherence to HER2-targeted therapies being evaluated for GEA
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here